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Abstract 
 
Overwhelming evidence clearly shows that the prevalence of obesity is dramatically 
increasing worldwide, and is associated with an increased risk of cardiovascular (CV) 
disease and metabolic disorders. The optimal dietary strategy for the prevention of chronic 
diseases remains a challenging and a highly relevant preventive health issue. Adrenaline 
(AD) and noradrenaline (NA), the main mediators of the sympathoadrenomedullary system, 
play crucial roles in the regulation of metabolic and CV homeostasis. Interestingly enough, 
relatively to metabolic syndrome, AD and NA seem to behave very differently: whereas NA 
levels positively correlate with obesity and CV risk, AD shows an inverse association with CV 
mortality.  
Fatty acids are not only an important direct source of energy but they also play key 
roles in regulating a range of physiological responses and the dysfunction of their 
metabolism can impair nervous control of energy homeostasis. The typical western diet is 
overloaded with omega-6 fatty acids and contains insufficient omega-3 fatty acids, and this 
dietary imbalance in fatty acids is a fundamental underlying cause of many chronic diseases 
including CV disease. In line with this, omega-3 fatty acids are usually associated with 
cardioprotective benefits. On the other hand, consumption of trans fatty acids, even at low 
levels of intake, significantly increases the risk of coronary events. Although fatty acids can 
have marked effects on neurosecretion, very limited information is available concerning the 
effect of these molecules on catecholamines (CA) handling by adrenal chromaffin cells.  
The aim of this work was to investigate the effect of several fatty acids on CA 
synthesis and secretion from chromaffin cells. Tyrosine hydroxilase (TH) and 
phenylethanolamine N-methyltransferase (PNMT) expression was also evaluated under the 
same conditions. For that purpose, the effect of chronic (24 hours) exposure to 
monounsaturated, trans and polyunsaturated fatty acids upon the above parameters was 
investigated, using bovine adrenal chromaffin cells. CA in cells and liquids were quantified by 
HPLC and mRNA levels of both enzymes were analyzed by relative quantification using 
quantitative real-time PCR.    
With the exception of oleic acid, all the unsaturated fatty acids tested influenced CA 
handling by adrenal chromaffin cells. Our results suggest that these fatty acids affected, 
through different pathways, the cellular content and release of CA, regardless both the 
number of carbon atoms and the localization of the first double bound. The fatty acids of 
omega-6 series differently affected CA handling: arachidonic acid seemed to impair the 
vesicular transport of CA and linoleic acid had the opposite effect, i.e. seemed to increase 
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this function, whereas γ-linolenic acid selectively impaired the availability of AD by interfering 
with its synthesis and release. Within the omega-9 fatty acids, elaidic acid, the 9-trans oleic 
acid isomer, behaved similarly to γ-linolenic acid, whereas, as previously mentioned, oleic 
acid was devoid of effect. Eicosapentaenoic and docosahexaenoic acids, belonging to 
omega-3 series, did not differentiate between AD and NA, and were able to impair both CA 
synthesis and release.  
Further studies are required to identify and characterize the intracellular responses 
involved in the actions of these unsaturated fatty acids over CA responses. That knowledge, 
together with data obtained from “in vivo” studies, might help to sustain future nutritional 
recommendations in order to improve health.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Key-words: Catecholamines, adrenaline, noradrenaline, bovine chromaffin cells, 
unsaturated fatty acids, TH and PNMT. 
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Resumo 
 
 
A prevalência da obesidade está a aumentar drasticamente em todo o mundo, 
estando associada a um risco aumentado de doença cardiovascular (CV) e alterações 
metabólicas. A procura de estratégias dietéticas que ajudem a prevenir estas doenças 
crónicas continua a ser um desafio extremamente importante. A adrenalina (AD) e a 
noradrenalina (NA), os principais mediadores do sistema simpatoadrenomedular, 
desempenham efeitos marcados no metabolismo energético e na homeostasia CV. 
Curiosamente, a AD e a NA parecem comportar-se de modo muito diferente na síndrome 
metabólica: enquanto os níveis de NA se associam positivamente com a obesidade e o risco 
CV, a AD apresenta uma associação inversa com a mortalidade CV.  
Os ácidos gordos são, não só uma importante fonte de energia, mas também 
exercem funções cruciais na regulação de várias respostas fisiológicas, e a alteração do seu 
metabolismo pode prejudicar o controlo central da homeostasia energética. A dieta típica 
ocidental apresenta uma sobrecarga de ácidos gordos ómega-6 e contem ácidos gordos 
ómega-3 em quantidade insuficiente, e este desequilíbrio dietético em ácidos gordos é uma 
causa importante subjacente a muitas doenças crónicas, incluindo doenças CV. De acordo 
com isto, os ácidos gordos ómega-3 estão geralmente associados a benefícios 
cardioprotetores. Por outro lado, o consumo de ácidos gordos trans, mesmo em baixas 
quantidades, aumenta significativamente o risco de eventos coronários. Apesar dos ácidos 
gordos poderem ter vários efeitos na neurosecreção, sabe-se ainda pouco sobre o efeito 
destas moléculas na disponibilidade de catecolaminas (CA) em células cromafins adrenais.  
O objetivo deste trabalho foi investigar o efeito de vários ácidos gordos na síntese e 
libertação de CA a partir de células cromafins. Além disso, avaliou-se a expressão da 
hidroxílase da tirosina (TH) e da feniletanolamina N-metil transférase (PNMT) nas mesmas 
condições experimentais. Para tal, usando células cromafins adrenais de Boi, avaliou-se o 
efeito da exposição crónica (24h) a ácidos gordos monoinsaturados, trans e polinsaturados 
nos parâmetros referidos acima. As CA nas células e líquidos foram quantificadas por HPLC 
e os níveis de RNAm das duas enzimas foram avaliados por quantificação relativa, usando 
PCR quantitativo em tempo real. À exceção do ácido oleico, todos os ácidos gordos 
insaturados afetaram a disponibilidade de CA nas células cromafins. Os nossos resultados 
sugerem que estes ácidos gordos afetam, através de diferentes mecanismos, o conteúdo 
celular e a libertação de CA, independentemente do número de átomos de carbono e da 
localização da primeira ligação dupla. Os ácidos gordos da série ómega-6 regularam de 
forma distinta as CA: o efeito do ácido araquidónico foi compatível com uma inibição do 
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transportador vesicular, o ácido linoleico pareceu aumentar a sua função e o ácido γ-
linolénico afetou seletivamente os níveis de AD, reduzindo a sua síntese e libertação. Na 
série ómega-9, o ácido elaídico, o isómero trans-9 do ácido oleico, comportou-se de forma 
semelhante ao γ-linolénico, enquanto o oleico, como referido anteriormente, não teve 
qualquer efeito. Os ácidos eicosapentaenóico e docosahexaenóico, da série ómega-3, não 
tiveram um efeito diferencial nas duas CA, reduzindo a síntese e libertação de ambas. 
Estudos posteriores serão necessários para identificar e caracterizar as respostas 
intracelulares envolvidas nas ações dos ácidos gordos insaturados sobre a disponibilidade 
de CA. Este conhecimento, juntamente com dados obtidos em modelos “in vivo”, poderá 
ajudar a fundamentar recomendações nutricionais no sentido de melhorar a saúde.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Palavras-chave: Catecolaminas, adrenalina, noradrenalina, células cromafins de Boi, 
ácidos gordos insaturados, TH e PNMT.
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1. Chromaffin cells in adrenal gland 
 
1.1. Adrenal gland 
 
Adrenal glands are located in the upper pole of each kidney and are surrounded by 
adipose tissue. In humans, each gland weights between 6 and 10g and has approximately 5 
by 3 cm. These glands are composed by two embryological different regions: cortex and 
medulla (1). Adrenal Cortex, which develops from mesoderm, is separated in three anatomic 
zones: glomerulosa, fasciculate and reticularis, respectively, the outer, intermediate and 
inner region of adrenal cortex (1-3). Adrenal Medulla is mainly constituted by chromaffin cells 
which derive from neural crest (4) and differentiate into: adrenergic or noradrenergic 
chromaffin cells, small intensely fluorescent cells, correspondent to the small granule cells 
observed by electron microscopy, and ganglionic neurons, either noradrenergic or 
cholinergic (3, 5). 
 
1.2. Chromaffin cells 
 
Chromaffin cells, the major cell type of the adrenal medulla, are arranged in cords 
around the blood capillaries (6). The term "chromaffin" is based on the yellow-brownish 
colour when cells are stained with chromic acid. Chromium salts oxidize and polymerize 
catecholamines (CA) resulting in a brownish-yellow colour (7).  
Adrenergic and noradrenergic chromaffin cells synthesize mainly the CA: 
noradrenaline (NA) and adrenaline (AD) from tyrosine (Tyr). NA is also synthesized in the 
central nervous system and sympathetic postganglionic neurons, whereas almost all of the 
AD is synthesized in the adrenal medulla (3). Among species, the ratio of adrenergic and 
noradrenergic cells is variable. For instance, rat chromaffin cells are predominantly 
adrenergic cells (80 ± 85%). In human and bovine glands, 75% of chromaffin cells are 
adrenergic, and the rabbit has a small proportion of noradrenergic cells. The relative 
proportion of these cells can reproduce distinct species-specific physiological needs (5).  
CA are synthesized by chromaffin cells, co-stored in large dense-core secretory 
granules with enkephalin, neuropeptide Y, atrial natriuretic factor, chromogranins, and tissue 
plasminogen activator and released directly into the circulation by exocytosis (6). Once in the 
bloodstream, CA act on target cells through binding to adrenergic receptors, exerting crucial 
roles in both homeostatic regulation and synchronized response to stress (the “fight-or-flight” 
response). The “fight-or-flight” response, firstly described by Walter Cannon (8), leads to an 
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increase of heart rate, contractility and vascular tone, an increase of blood flow to skeletal 
muscle, a suppression of insulin release and mobilization of glucose from liver.  A long 
exposure to stressors can be harmful to health. In fact, high plasmatic CA levels are involved 
with several features of metabolic syndrome and cardiovascular disease (9). 
 
1.2.1. Biosynthesis and metabolism of catecholamines 
 
1.2.1.1. Catecholamine biosynthesis 
The biosynthesis of CA (Figure 1) begins by the conversion of the amino acid Tyr  to 
dihydroxyphenylalanine (DOPA). Tyr is a non-essential amino acid, which can be obtained 
from diet or from hydroxylation of phenylalanine in liver. Tyr, after uptake by adrenal 
chromaffin cells, is converted in cytosol to DOPA by tyrosine hydroxylase (TH), the rate-
limiting step of CA synthesis (10). TH is a soluble cytoplasmic enzyme which use 
tetrahydrobiopterin (BH4) as cofactor and molecular oxygen in the reaction that originates 
DOPA, dihydrobiopterin and water (11). The next step is the synthesis of dopamine (DA) 
from DOPA, catalyzed by a nonspecific enzyme, L-aromatic amino acid decarboxylase 
(AAAD), also known as dopa decarboxylase (DDC), which uses pyridoxal phosphate as 
cofactor.  
After its synthesis, DA is stored in large dense-core secretory granules and converted 
into NA by dopamine-β-hydroxylase (DβH). This enzyme is co-released with NA and AD by 
exocytosis (12).  
The last enzymatic step of CA biosynthesis pathway is catalyzed by the soluble 
cytoplasmic enzyme phenylethanolamine N-methyltransferase (PNMT), which uses S-
adenosyl-methionine as cofactor, for the conversion of NA to AD (13). 
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Figure 1. Catecholamine biosynthesis pathway. 
In catecholamine synthesis, tyrosine hydroxylase catalyzes the conversion of the amino acid tyrosine to DOPA. Then, DOPA is 
converted to dopamine by dopa decarboxylase. In chromaffin granule, dopamine is converted to noradrenaline by dopamine-β-
hydroxylase. Finally, in the cytoplasm, phenylethanolamine N-methyltransferase catalyzes the conversion of noradrenaline to 
adrenaline. 
 
1.2.1.2. Catecholamine metabolism 
Monoamine oxidase (MAO) and catechol O-methyltransferase (COMT) are the two 
enzymes responsible for CA metabolism. MAO is mainly associated with mitochondrial 
surface and plays an important role in cytoplasmatic CA metabolization by deamination. On 
the other hand, COMT, predominantly localized in the cytoplasm, requires Mg2+ for 
transferring a methyl group from S-adenosylmethionine to the 3-hydroxyl group of the 
A 
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catechol ring of CA, originating normetanephrine (NMN) from NA and metanephrine (MN) 
from AD (14). 
In CA metabolism, NA and AD are initially deaminated by MAO to 3,4-
dihydroxyphenylglycolaldehyde (DOPEGAL). Then, this aldehyde is reduced to 3,4-
dihydroxyphenylglycol (DHPG) by aldehyde reductase, or, otherwise, undergoes oxidation by 
the action of aldehyde dehydrogenase originating the 3,4-dihydroxymandelic acid (DHMA) 
(Figure 2 A).   
On the other hand, AD and NA can be methylated by COMT, respectively, to MN and 
NMN (Figure 2 B). NMN and MN are oxidized by MAO, and originate 3-methoxy-4-
hydroxyphenylglycolaldehyde (MOPEGAL). MOPEGAL is reduced to 3-methoxy-4-
hydroxyphenylglycol (MHPG) by aldehyde reductase, or it can also be oxidized to 
vanillylmandelic acid (VMA). In addition, DOPEGAL can be converted to DHPG by aldehyde 
reductase. DHPG is converted to MHPG by COMT. Finally, MHPG is converted to 
MOPEGAL, and is oxidized to VMA (14, 15). 
 
 
Figure 2. Metabolism of catecholamines. 
A) Pathways of oxidative deamination of catecholamines to their corresponding biogenic aldehyde intermediates and acid 
derivate or alcohol metabolites. B) Pathways of NA metabolism to vanillylmandelic acid. DβH: dopamine β-hidroxylase; PMNT: 
phenylethanolamine N-methyltransferase; MAO: monoamine oxidase; COMT: catechol-O-methyltransferase; ALD: aldehyde 
dehydrogenase; AR: aldehyde reductase; ADH: alcohol dehydrogenase; DA: dopamine; NA: noradrenaline; AD: adrenaline; 
DHMA: 3,4-dihydroxymandelic acid; DOPAL, 3,4-dihydroxyphenylacetaldehyde; DOPET: 3,4-dihydroxyphenylethanol; DOPAC: 
3,4-dihydroxyphenylacetic acid; DOPEGAL: 3,4-dihydroxyphenylglycolaldehyde; NMN: normetanephrine; DHPG: 3,4-
dihydroxyphenylglycol; MHPG: 3-methoxy-4-hydroxyphenylglycol; MOPEGAL: 3-methoxy-4-hydroxyphenylglycolaldehyde; 
VMA: vanillylmandelic acid. Thick arrows indicate predominant mechanism of degradation. Adapted from Eisenhofer et al. (14). 
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1.2.2. Regulation of catecholamine handling 
 
 
Figure 3. Mechanisms for maintaining the intracellular content of catecholamines. 
A) release of catecholamines by exocytosis, B) passive output of catecholamines to cytoplasm (leakage); C) metabolism of 
catecholamines; D) reuptake of catecholamines by membrane transporters (e.g. NET), E) uptake of catecholamines from the 
cytoplasm to the chromaffin granules by vesicular monoamine transporters (VMATs). Adapted from Eisonhefer et al. (16). 
 
Several mechanisms regulate CA intracellular content: (1) CA storage; (2) leakage; 
(3) CA re-uptake and (4) CA release (basal release and exocytosis). 
Generally, low concentrations of CA are free in the cytosol and can be metabolized by 
MAO and COMT. However, this metabolization process occurs before and independently of 
exocytosis. After the conversion of Tyr, both NA and AD can be stored in chromaffin granules 
(Figure 3 E). These granules contain very high concentrations of CA, ascorbic acid, 
adenosine-5'-triphosphate (ATP), acidic proteins (chromogranins) and DβH.  The vesicular 
monoamine transporters (VMATs), located in chromaffin granules membranes, have 12 
transmembrane domains with N- and C-terminal in the cytoplasm (17). The CA capture into 
secretory granules, is an ATP-dependent process associated with a proton pump (18).   
Leakage is another mechanism that regulates the intracellular content of CA, and is 
characterized by a passive exit of CA from granules into cytoplasm (Figure 3 B). Leakage is 
balanced by the re-entry of about 90% of CA into chromaffin granules by VMATs (16). 
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After release, about 90% of CA are re-captured into the chromaffin cells by the 
membrane transporter NET (Figure 3 D). The released CA enter bloodstream and/or are 
metabolized. In rat and human chromaffin cells, this transporter is only present in adrenergic 
cells but is responsible for the re-uptake of both CA (19). CA levels influence the expression 
of this transporter: high concentrations of CA increase the number of transporters, and low 
concentration of CA lead to a decrease of their density (20).  
The secretory content (including CA and peptides, among others) of chromaffin 
granules is released by exocytosis (Figure 3 A and Figure 4). A strong stimulation provokes 
the release of about 200 chromaffin granules per cell (calculated average for a single cell) 
(21). CA are released through two types of exocytosis: constitutive or regulated. Constitutive 
exocytosis is a continuous process that occurs without any stimulus, whereas the regulated 
exocytosis occurs after an external stimulus, which leads to an increase of intracellular Ca2+ 
(22). ‘‘Full fusion’’ exocytosis, ‘‘kiss-and-run’’ exocytosis and piecemeal degranulation are the 
three forms of exocytosis already described (21). 
In chromaffin cells, acetylcholine released by the splanchnic nerve is the main 
physiologic secretagogue for CA release, exerting this effect through binding to muscarinic 
and nicotinic receptors. Activation of nicotinic receptors leads to extracellular Ca2+ and Na+ 
entrance into the cells, causing a slight membrane depolarization and leading to the opening 
of Na+ voltage sensitive channels. This event causes a large cytoplasmic membrane 
depolarization, inducing the opening of several types of voltage-dependent Ca2+ channels 
thus increasing intracellular Ca2+ from the extracellular compartment (5, 23, 24). On the other 
hand, activation of muscarinic receptors leads to the production of inositol trisphosphate 
(IP3) and diacylglycerol (DAG) after activation of phospholipase C (PLC). Afterwards, IP3 
stimulates the release of sequestered Ca2+ in stores, leading to an increased concentration 
of cytoplasmatic Ca2+ (5). Ca2+ together with DAG can then activate protein kinase C (PKC), 
which plays an important role in the regulation of exocytosis, through its involvement in the 
phosphorylation of proteins responsible for vesicle docking, priming and fusion (25).  
In the resting state, the network of filamentous actin which forms the cellular 
cytoskeleton prevents the traffic of chromaffin granules to the plasma membrane. (26). The 
increase of intracellular Ca2+ levels leads to the disruption of this cytoskeleton, allowing 
exocytosis (27).  
In chromaffin cells, exocytosis is an extremely regulated mechanism (5). Besides 
acetylcholine, several other agents regulate CA release, such as other nicotinic or muscarinic 
agonists, bradykinin, angiotensin II, histamine, ATP, depolarization by KCl, among others.  
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Figure 4. Full fusion of exocytosis. 
A) Full fusion exocytosis. After stimulation, plasma membrane calcium channels open, allowing an influx of Ca
2+
. 
Consequently, the secretory granules move up to the plasma membrane, dock and prime for fusion. After fusion catecholamines 
are released.  
B) Anchoring process of chromaffin granules. Watching closely, the secretory granule is docked at plasma membrane 
between two Ca
2+
 channels. Both syntaxin and SNAP-25 (plasma membrane proteins) and the synaptobrevin (a vesicle protein) 
constitute an essential complex for fusion. Ca
2+ 
sensor, which triggers fusion, is synaptotagmin. The release can be influenced 
by more than one calcium channel because synaptotagmin can be detached from the calcium channel. Adapted from Matthews, 
G. (23).  
 
1.2.3. Adrenergic receptors 
 
After release, CA exert their physiologic effects by activation of the plasma membrane 
receptors, adrenergic receptors or adrenoreceptors (28). Adrenoreceptors belong to the 
superfamily of G protein-coupled receptors (GPCR) (15). These receptors are single 
proteins, with an extracellular amine terminal (NH2) (with glycosylation sites) and an 
intracellular carboxylic terminal (COOH) (with phosphorylation sites). These receptors have 
seven transmembrane domains interconnected by three extracellular hydrophobic loops and 
three intracellular loops. Both second and third intracellular loops are linked to G proteins 
subunits (15) (Figure 5).They are divided in two major classes: α and β.  
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Figure 5. Structure of adrenergic receptors. 
The structure of this receptor is characterized by an extracellular NH2 terminal, intracellular COOH and seven transmembrane 
domains in hydrophobic helix, which are interconnected by three extracellular hydrophobic loops and three intracellular loops. 
Adapted from García-Sáinz et al. (29). 
 
1.2.3.1. α- Adrenoreceptors 
α-adrenoreceptors include two subclasses: α1 and α2. α1-adrenoreceptors can 
stimulate polyphosphoinositide hydrolysis leading to the formation of IP3 and DAG. As 
mentioned before, IP3 promotes the release of sequestered Ca2+ from intracellular stores, 
which increases the cytoplasmatic concentration of free Ca2+ and the activation of various 
calcium-dependent protein kinases, and DAG activates PKC. α1-adrenoreceptors have been 
also found to activate mitogen-activated kinases (MAPK) and polyphosphoinositol-3-kinase 
(PI-3-kinase) (29, 30). α2-adrenoreceptors inhibit adenylyl cyclase activity and cause 
intracellular cAMP levels to decrease. α2-adrenoreceptors inhibition of adenylyl cyclase 
occurs through the mediation of the inhibitory regulatory protein, Gi, that couples to α2-
adrenoreceptors inhibiting adenylyl cyclase. In addition, some of the effects of α2-
adrenoreceptors are independent of their ability to inhibit adenylyl cyclase; for instance 
activation of potassium channels and closing of calcium channels. These actions may be 
mediated by G proteins of the Gi/Go class (28). 
 
1.2.3.2. β-Adrenoreceptors 
CA binding to the three β-adrenoreceptors subtypes (β1, β2 and β3), results in 
activation of adenylyl cyclase and increased conversion of ATP to cAMP. Activation of this 
enzyme is mediated by the stimulatory coupling protein, Gs. cAMP is the major second 
messenger of β-adrenoceptors activation (28). 
In the scope of this work, it is relevant to highlight in this section that in humans, CA 
are responsible for the mobilization of lipids from adipose tissue. Indeed, lipolysis, the 
process through which triglycerides are hydrolyzed into glycerol and fatty acids, results from 
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the balance between the lipolytic effect of β-adrenergic receptors and the antilipolytic effect 
of α2-adrenergic receptors (31).  
 
 
2. Fatty acids  
 
As reviewed before (32), fatty acids can be classified by chain length and double 
bound number (Table 1). 
Table 1. Classification of fatty acids. 
 Adapted from Pilz, S. et al. (32). 
Chain length (number of carbons) 
Short-chain fatty acids: < 8 carbons 
Medium-chain fatty acids:  8 – 12 carbons 
Long-chain fatty acids: 13 – 22 carbons 
Very-long-chain fatty acids:  > 22 carbons 
Double bound number 
Saturated fatty acids (SFA) 
Monounsaturated fatty acids (MUFA) 
Polyunsaturated fatty acids (PUFA) 
 
From a nutritional point of view, fatty acids can be classified as essential or non-
essential. The essential fatty acids are not synthesized in the body and are mostly obtained 
from diet, whereas non-essential fatty acids can be synthesized by human body from other 
fatty acids (Figure 6). 
The type and quantity of dietary fat is a significant risk factor for cardiovascular 
disease and some cancers, with the result that health organizations generally recommend 
reducing the intake of saturated fatty acids in favor of more mono- and poly-unsaturated fatty 
acids (33).  
For instance, the typical Western diet is overloaded with omega-6 fatty acids and 
contains insufficient omega-3 fatty acids. The ratio of omega-6 to omega-3 fatty acids is 
generally >10:1, whereas on a primitive human diet it was closer to 1:1 (33). This imbalance 
in dietary fatty acids is associated with many chronic diseases including cardiovascular 
diseases and some cancers (34).  
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Figure 6. Metabolic pathways of omega-3, omega-6 and omega-9 fatty acids synthesis. 
Polyunsaturated linoleic and α-linolenic acids are essential fatty acids. Omega-3 and omega-6 fatty acids are polyunsaturated 
whereas omega-9 oleic and elaidic acid are monounsaturated fatty acids. The desaturase enzymes allow the formation of 
double bond and the elongation process consists in adding carbon atoms. Through elaidinisation, oleic acid is converted to its 
trans isomer, elaidic acid. Adapted from Beaudoin et al. (35). 
 
 
2.1. Omega – 3 fatty acids 
 
Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), highly present in 
Western diet, are abundantly present in eggs, white meet such as chicken and turkey, and 
plant oils,  flesh of fatty fish and oily fish. They are also available as supplements, such as 
fish oils (containing 30% - 50% of omega-3 fatty acids) or concentrated pharmaceutical 
preparations (34, 36). Both EPA and DHA are non-essential fatty acids since they are 
synthesized from alpha-linolenic acid, an essential fatty acid (Figure 6). 
Omega-3
α-Linolenic acid
(18:3 n-3)
Octadecatetraenoic
acid
(18:4 n-3)
Eicosatetraenoic
acid
(20:4 n-3)
Eicosapentaenoic
acid
(20:5 n-3)
Docosopentaenoic
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(22:5 n-3)
Docosahexaenoic
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(22:6 n-3)
Omega-6
Linoleic acid
(18:2 n-6)
γ-Linolenic acid
(18:3 n-6)
Di-homo-γ-
Linolenic acid
(20:3 n-6)
Arachidonic acid
(20:4 n-6)
Δ-6 desaturase
Elongation
Δ-5 desaturase
Elongation
Δ-4 desaturase
Stearic acid
(18:0)
Oleic acid
(18:1 n-9)
Elaidic acid
(18:1 n-9)
Elaidinisation
Δ-9 desaturase
Omega-9
Saturated
fatty acid
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EPA and DHA consumption is associated with cardioprotective benefits due to their 
multiple physiological effects on lipids, blood pressure, vascular function, cardiac rhythms, 
platelet function and inflammatory responses (36-38). They also alter insulin sensitivity and 
decrease tumor growth and metastasis (37). In fact, as reviewed before, omega-3 fatty acids 
revealed several beneficial effects on cardiovascular system, through their involvement in 
various intracellular mechanism: regulation of Ca2+ channels, phospholipid degradation and 
eicosanoids production (39).  
From a biochemical point of view, in omega-3 family the position of the first double-
bond occurs between the third and the fourth carbon counting from the methyl end (omega 
end). DHA has twenty two carbon atoms and six cis double bonds (22:6 n-3) (Figure 7 B), 
whereas EPA has twenty carbon atoms and five cis double bonds (20:5 n-3) (Figure 7 A).  
 
Figure 7. Chemical structure of the omega-3 fatty acids: A) eicosapentaenoic acid B) docosahexaenoic acid. 
 
2.2. Omega – 6 fatty acids 
 
Linoleic acid (LA) is the major omega-6 fatty acid found in Western diet. It is present 
in vegetable oils as soybean, safflower, and rapeseed oils, among others. LA is an essential 
fatty acid, mostly obtained from diet. Both γ-linolenic acid (γ-LIN) and arachidonic acid (AA) 
can be synthesized from LA and can be also found in Western diet, being present in meat, 
poultry and eggs. 
The role of omega-6 fatty acids in cardiovascular disease prevention remains 
controversial. These fatty acids are implicated in a higher susceptibility for lipoproteins (low-
density lipoproteins (LDL) and very low-density lipoproteins (VLDL)) oxidation, a possible 
mechanism linking an enriched diet in omega-6 fatty acids and cardiovascular diseases (34). 
On the contrary, some authors have reported that the replacement of saturated fatty acids 
content with omega-6 fatty acids decrease plasma cholesterol levels and blood pressure and 
can reduce the risk for cardiovascular diseases (34, 40, 41). In spite of this controversy, one 
of the main concerns regarding the dietary intake of omega-6 fatty acids is their conversion 
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into eicosanoids, a family of mediator molecules involved in immune and inflammatory 
responses. As a matter of fact, AA is a precursor of prostaglandin E2 (PGE2) and 
leukotrienes B4, which exert marked inflammatory effects. However, higher intakes of these 
fatty acids do not seem to be associated with elevated inflammatory markers levels (40). 
Nonetheless, the competition between omega-6 and omega-3 metabolism results in a 
reduced production of anti-inflammatory molecules from omega-3 polyunsaturated fatty 
acids. In fact, some researchers recommend reducing dietary omega-6 polyunsaturated fatty 
acids intake in order to prevent adverse effects on health, in particular pro-inflammatory 
responses (40).  
Biochemically, omega-6 fatty acids have the first unsaturation between the sixth and 
the seventh carbon counting from the omega end. LA  has two cis double bonds and 
eighteen carbon atoms (18:2 n-6) (Figure 8 A), γ-LIN has eighteen carbon atoms and three 
cis double bonds (18:3 n-6)  (Figure 8 B) and AA has twenty carbon atoms and four cis 
double bonds (20:4 n-6) (Figure 8 C). 
 
 
 
Figure 8. Chemical structure of the omega-6 fatty acids: A) linoleic acid, B) γ- linolenic acid and C) arachidonic acid. 
 
2.3. Omega – 9 fatty acids 
 
Oleic acid (OA), the major fatty acid present in olive oil, has been regarded as having 
protective effects against oxidative stress and immune and inflammatory responses (42).  
Trans fatty acids have been shown to have a significant adverse influence on serum 
lipids and lipoproteins levels and inflammation, increasing cardiovascular risk (43-45). Trans 
fatty acids gained popularity as a mean of replacing saturated fatty acids in diet, but now are 
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believed to be nutritionally unnecessary. Trans fatty acids can be obtained from natural and 
artificial sources. In the rumens of ruminant animals, trans fatty acids are formed naturally by 
microflora (an isomerase converts the configuration cis into trans). Thus, dairy and meat 
products contain small amounts of these molecules (2-9% of total fat) (44). Artificial trans 
fatty acids are produced from partial hydrogenation of  liquid vegetable oils and are present 
in a variety of products, such as modified vegetables oils, both sweet and salty snacks, 
sauces, instantaneous soups and fast foods (45).  
Elaidic acid (EA) is the isomer with higher concentration in industrial sources of trans 
fatty acids, representing 80-90% of total trans fatty acids in foods (45).  
Omega-9 fatty acids are monounsaturated with the double bond between the ninth 
and the tenth carbon counting from the methyl end. OA has one cis double bond and 
eighteen carbon atoms (18:1 n-9) (Figure 9 A), whereas EA has the same number of carbon 
atoms but a trans double bond (18:1 n-9) (Figure 9 B). The double bonds in trans fatty acids 
present a linear shape with the hydrogen atoms in opposite sides of the molecule, originating 
a more rigid configuration which requires a melting point around room temperature, highly 
desirable in food industry (46). 
 
 
 
Figure 9. Chemical structure of the omega-9 fatty acids: A) oleic acid and B) elaidic acid. 
 
 
2.4. Cellular uptake of fatty acids  
 
A great amount of evidences suggest that long-chain fatty acids enter cells by a 
protein-mediated saturable uptake thought to contribute to the majority of cellular long-chain 
fatty acids capture (Figure 10). Several proteins have been implicated in cellular fatty acids 
uptake including: scavenger receptor CD36  (47); plasma membrane fatty acid binding 
protein (FABPpm); six fatty acid transport proteins (FATP); long-chain acyl-CoA synthetase 
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(LACS) (48). The mechanisms implicated in the regulation of these transporters are currently 
under study.  
 
 
Figure 10. Fatty acid transport across the cell membrane. 
CD36, alone or together with peripheral membrane protein accepts fatty acids at the cell surface to increase their local 
concentration and increase fatty acids diffusion. It is also possible that CD36 actively transports fatty acids across the 
membrane. Long-chain fatty acids are transported by fatty acid transport proteins. Once at the inner side of the membrane, fatty 
acids are bound by plasma membrane fatty acid binding protein. FATP: fatty acid transport proteins; FABPpm: plasma 
membrane fatty acid binding protein; FABPc: cytosolic fatty acid binding protein; FA: fatty acids. 
 
 
3. Catecholamines and metabolic syndrome 
 
In obesity and associated morbidities, the mechanisms underlying the parallel 
activation of the sympathetic nervous system and of adrenal medulla activity are complex 
and not clearly understood (49). However, evidence collected throughout the last two 
decades has unequivocally shown that major features of the metabolic syndrome (e.g. 
hypertension, visceral obesity and diabetes) are associated with markers of sympathetic 
overdrive (50-52). CA have many effects on glucose and lipid metabolism leading to impaired 
glucose tolerance and insulin resistance. Indeed, CA stimulate liver glycogenolysis and 
gluconeogenesis and inhibit insulin sensitivity and glucose uptake in the skeletal muscle. On 
the other hand, in humans, CA are responsible for the mobilization of lipids from adipose 
tissue. Indeed, lipolysis results from the balance between the lipolytic effect of β-adrenergic 
receptors and the antilipolytic effect of α2-adrenergic receptors (31). Fatty acids are 
important as metabolic substrates and as structural components of biological membranes. 
However, they also function as signaling molecules, regulating a large range of physiological 
responses (53). Fatty acids overload or dysfunction of their metabolism could contribute to 
development of obesity and/or type 2 diabetes in predisposed subjects. To date, although 
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some studies (54, 55) reported that fatty acids can have profound effects on neurosecretion, 
very little is known about the effect of these molecules on CA handling by adrenal chromaffin 
cells. Interestingly enough, it has already been shown that some saturated fatty acids 
differently affect CA handling by adrenal  chromaffin cells (56).  
 
 
4. Aim 
 
This work aimed to investigate the effect of several fatty acids on CA synthesis and 
secretion from chromaffin cells. For that purpose, the effect of chronic exposure to 
monounsaturated, polyunsaturated and trans fatty acids on the CA cellular content and 
release was investigated, using bovine adrenal chromaffin cells. The effect of these 
molecules on TH, the rate limiting enzyme of the CA synthesis, and on PNMT, the enzyme 
that converts NA to AD, expression was also evaluated. 
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1. Preparation of adrenal medullary cells 
 
Bovine adrenal glands were obtained from a local slaughterhouse and were 
processed for cell culture within 2 hours of slaughter, being transported to the laboratory in 
ice-cold Ca2+–Mg2+ -free Buffer A1 .The chromaffin cells were isolated by digestion with 
collagenase A as described by Livett et al. (57, 58) with some modifications.  
Briefly, the adrenal glands were trimmed of fat and washed with Ca2+–Mg2+ -free 
Buffer A. The buffer was injected into the adrenal vein in order to wash the remaining blood 
from the gland. The adrenal glands were digested with a Ca2+–Mg2+-free Buffer A containing 
0.25% collagenase A and 0.01% DNAse I. Five ml of this solution was injected into the 
adrenal vein of each gland. This procedure was repeated every 15 minutes with the glands 
incubated at 37 °C in Ca2+–Mg2+ -free Buffer A. After 45 minutes, the digested medullary 
tissue was mechanically separated from the adrenal cortex and incubated in Buffer A, 
containing collagenase A, for 30 minutes at 37 °C. Subsequently, cells were filtered through 
a 200 μm nylon mesh. Afterwards, filtered cells were centrifuged 3 × at 1000 g for 3 minutes 
and washed with Ca2+–Mg2+ -free Buffer A in order to remove the collagenase A/DNAse. At 
last, they were filtered through a 100 μm nylon mesh. 
 
 
2. Cell culture 
 
Bovine chromaffin cells were cultured in Dulbecco's Modified Eagle's medium 
(nutrient mixture F-12 Ham (1:1), supplemented with 10% fetal calf serum, 2 nM L-glutamine, 
15 mM HEPES, 10 µM cytosine arabinoside, 100 units/ml penicillin, 100 mg/ml streptomycin 
and 0.25 µm/ml amphotericin B). 
The dispersed cells were plated in collagen-coated 24-well plastic culture dishes (2 
cm2; Æ 15.6 mm) at a density of 4-5 x 105-106 cells/well and incubated at 37 °C in an 
atmosphere consisting of 5% CO2 in air and with 99% of relative humidity. The day of cell 
preparation and cell seeding was described as day 0. Culture medium was replaced every 24 
hours and, for the experiments, cells were used after 4 days in culture. 24 hours before 
experiment, culture medium was made free of fetal calf serum (59). 
 
 
                                                          
1
 Ca2+–Mg2+ -free Buffer A:154 mM NaCl, 2.6 mM KCl, 0.85 mM KH2PO4, 2.15 mM K2HPO4, 10 mM glucose and 12.7 mM 
HEPES, pH 7.4 
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3. In vitro experiments 
 
3.1.  Chronic treatment with fatty acids 
 
After 4 days in culture, and before the studies on  CA handling, cells were incubated 
for 24 hours (chronic exposure) with ethanol or DMSO (controls), linoleic acid (18:2n-6; 50-
100 µM), γ-linolenic acid (18:3n-6; 50-100 µM), docosahexaenoic acid (22:6n-3; 50-100 µM), 
eicosapentaenoic acid (20:5n-3; 50-100 µM), arachidonic acid (20:4n-6; 50-100 µM), oleic 
acid (18:1n-9, cis; 50-100 µM) or oleic acid's trans isomer, elaidic acid (18:1n-9, trans;  50-
100 µM). The tested concentrations of fatty acids (50-100 µM) are considered to be within 
the range of physiological concentrations (60). Fatty acids were dissolved with either ethanol 
or DMSO (0.1% (v/v)). 
 
3.2. Studies on catecholamine handling 
 
After the chronic treatment with the several fatty acids, cells were pre-incubated for 
10 min, at 37 °C in order to study basal release. Initially, the culture medium was removed 
and cells were washed with medium at 37 °C. Afterwards, cells were incubated for 15 
minutes in the absence (control) or presence of KCl (50mM). Incubation was stopped by 
rinsing the cells with ice-cold medium (4° C). At last, cells were solubilized with 0.3 ml 0.1% 
(v/v) Triton X-100 (in 5 mM Tris.HCl, pH 7.4) and placed at 37°C overnight. 
 
 
4. Determination of catecholamines by high pressure liquid chromatography 
with electrochemical detection  
  
CA cellular content and release were determined by high pressure liquid 
chromatography with electrochemical detection (HPLC-ED) using the methodology described 
by Soares-da-Silva et al. (61). 
The HPLC system consists in a pump (Gilson model 302; Gilson Medical Electronics, 
Villiers le Bel, France) connected to a manometer (Gilson model 802 C) and an ODS 5 µm 
steel column (Biophase; Bioanalytical Systems, West Lafayette, IN, USA), 25 cm long. The 
samples were injected by an automatic injector (Gilson model 321), connected to a Gilson 
diluter (model 401). The mobile phase consisted in a degassed solution of citric acid (0.1 
mM), 1-octanesulfonic acid sodium salt (OSA) (0.5 mM), ethylenediaminetetraacetic acid 
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(EDTA) (0.17 mM), dibutylamine (1mM), methanol (8% v/v) and was adjusted to pH 3.5 with 
perchloric acid, being pumped at a rate of 1 ml/min.  
The CA detection was performed electrochemically with a carbon electrode, an 
electrode Ag/AgCl and an amperometric detector (Gilson model 141). The detector cell was 
adjusted to 0.75 V. The originated current was monitored via software Gilson HPLC 172. The 
lower limits of CA detection varied from 350 to 1000 fmol. 
 
 
5. Determination of enzymatic expression by quantitative real-time PCR  
 
After a 24 hours treatment with the several fatty acids, total RNA was extracted from 
cells using the Tripure isolation reagent, according to manufacturer’s instructions. After 
removing the culture medium, Tripure was added and the lysate was transferred to an 
eppendorf tube. Three layers were obtained after the chloroform addition (Figure 11).  
 
 
 
Figure 11. Layers obtained after centrifugation with chloroform in RNA extraction, by Tripure. 
 
The first layer, corresponding to RNA, was isolated and treated with isopropanol for 
RNA precipitation and was washed with ethanol (75% ethanol in diethylpyrocarbonate 
(DEPC)). Afterwards, five micrograms of RNA were used as template for complementary 
DNA production through the incubation with SuperScript-II reverse transcriptase (200 U/µl) at 
65 °C with 50 ng/µl random hexamers, 10 mmol/l per deoxyribonucleotide triphosphate, 40 
U/µl RNase inhibitor. After, 5X First-Strand Buffer (250 mM Tris-HCl, pH 8.3 at room 
temperature; 375 mM KCl; 15 mM MgCl2), 0.1M DTT and RNaseOUT™(40 U/µl) were added 
and incubated at 25° C during 2 minutes. Reverse Transcriptase SSII was included, 
incubating at 25° C during 10 minutes, followed by 50 minutes at 42° C and 70° C for 15 
minutes. Samples were incubated with 1 µl RNAse H for 20 min at 37 °C. 
With exception of AA treatment, after cDNA synthesis, TH and PNMT mRNA 
expression levels were analyzed by relative quantification using quantitative real-time PCR 
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(qRT-PCR) with SYBR Green I detection. The qRT-PCR was performed in a StepOne™ 
qPCR machine (Applied Biossystems™) and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) was used as endogenous control to normalize the results. The default 
thermocycler conditions have been used for all genes: 10 minutes of pre-incubation at 95° C 
followed by 40 cycles for 15 seconds at 95° C and one minute at 60° C. The quantification 
reactions were carried out in 20 µl volumes in a 48-well plate (Applied Biossystems™) 
containing 300 nM of forward and reverse primers, 1X FastStart universal SYBR green 
master (ROX) (Roche™) and aproximadely 21µl of cDNA. The data analysis was carried out 
using the StepOne™ Software version 2.2 (Applied Biossystems™) with the same baseline 
and threshold set for each plate, in order to generate threshold cycle (Ct) values for both 
genes in each sample. 
In the case of AA, qRT-PCR was carried out using a LightCycler (Roche, Nutley, NJ, 
USA). Twenty microliter reactions were set up in microcapillary tubes using 0.5 µmol/L of 
each primer and 4 µl of SYBR Green master mix (LightCycler FastStart DNA MasterPlus 
SYBR Green I). Cycling conditions were as follows: denaturation (95°C for 5 min), 
amplification and quantification [95°C for 10 s, annealing temperature for 10 s, and 72°C for 
10 s, with a single fluorescence measurement at the end of the 72°C for 10 s segment] 
repeated 55 times, a melting curve program [(annealing temperature +10)°C for 15 s and 
95°C with a heating rate of 0.1°C/s and continuous fluorescence measurement], and a 
cooling step to 40°C for 30 s. Data were analyzed using LightCycler® 4.05 analysis software 
(Roche, Mannheim, Germany). The amount of mRNA of each studied gene was normalized 
to the amount of mRNA of the housekeeping gene (GAPDH).  
 
Table 2. Primer sequences and annealing temperature (AT) used for quantitative real-time PCR 
 
Gene Sequence (5’ => 3’) AT (°C)  
bGAPDH 
Fwd: CGA CAC TCA CTC TTC TAC CTT 
65 
Rev: GTC CAC CAC CCT GTT GCT GTA 
bTH 
Fwd: ATC ATG TCC CCA CGC TTC GTC 
62 
Rev: GCC TTC CCG TCC CTC TCC AC 
bPNMT 
Fwd: CTA CCT CCG CAA CAA CTA CGC 
65 
Rev: TGT CCT CAA AGT GGG CAC AG 
 
bTH, bovine tyrosine hydroxylase; bPNMT, bovine phenylethanolamine N-methyltransferase; bGAPDH, bovine glyceraldehyde-
3-phosphate dehydrogenase; Fwd, forward; Rev, reverse. 
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6. Determination of cellular viability 
 
The effect of chronic exposure to fatty acids on cell viability was assessed by MTT [3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] method. MTT method is based 
on the activity of a mitochondrial dehydrogenase which cleaves an yellow dye (MTT), forming 
purpur crystals of formazan, this reaction occuring only in viable cells. The amount of product 
formed was determined spectrophotometrically (62). 
Initially, culture medium was removed and cells were incubated during 3 hours with 
MTT. After this time, extracellular medium was discharged and dimethyl sulfoxide (DMSO) 
added in order to solubilize formazan compounds. The absorbance was read at 540 nm, and 
the results were expressed as a percentage of control (62). 
 
 
7. Determination of proteins 
 
After solubilization of cells with 0.3 ml 0.1% (v/v) of Triton X-100 (in 5 mM Tris.HCl; 
pH 7.4), protein content was determined as described by Bradford (63), with human serum 
albumin as standard. 
 
 
8. Calculations and statistics 
 
The release of CA into the medium was calculated during periods A and B, 
corresponding to the first 10 min and to the following 15 min incubation periods, respectively. 
Release of CA from bovine adrenal chromaffin cells into the incubation medium during 
periods A or B was expressed as total, which corresponds to the amount of CA released into 
the medium in relation to the total cellular content of CA at the beginning of the release 
period. Basal release corresponds to release (expressed as % total) during period A. CA 
release, under different experimental conditions, is expressed as the percentage of basal 
release, or as the percentage of respective controls. Arithmetic means are given with SEM. 
For comparison between two groups, Student's t-test was used.  
Regarding qRT-PCR, data analysis was carried out using the computer software 
SPSS for Windows (version 19). The relative expression was determined using the 2-ΔΔCt 
method (64), and expression values were normalized to GAPDH. The 2-ΔΔCt method, along 
with Student’s t-test or Mann-Whitney U test, were used in order to evaluate statistical 
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differences in the normalized expression of the targets analyzed among the different 
experimental conditions tested.  
The P value obtained was considered statistically significant under 0.05. 
 
 
9. Materials  
 
EPA (eicosapentaenoic acid), DHA (docosahexaenoic acid); LA (linoleic acid); Υ-LIN (Υ 
linolenic acid); AA (arachidonic acid); OA (oleic acid); EA (elaidic acid), MTT 
(Methylthiazolyldiphenyl-tetrazolium bromide), Dulbecco's Modified Eagle's medium/F12,  
OSA, Tris (tris-(hydroxymethyl)-aminomethane hydrochloride), fetal calf serum, L-glutamine, 
HEPES, cytosine arabinoside, penicillin, streptomycin, amphotericin B, inhibitor of RNAses, 
pargyline, perchloric acid, collagenase A,  ascorbic acid (Sigma, St. Louis, MO, USA); 
Albumin, EDTA, Titron X-100, methanol, citric acid, D (+) glucose (Merck, Darmstadt, 
Germany); SuperScript™ II Reverse Transcriptase, RNAse H, GAPDH, SYBR Green I 
detection, chloroform (Invitrogen, Life Technologies, USA); Tripure isolation reagent (Roche 
Diagnostics, Germany).  
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In order to assess whether unsaturated fatty acids alter CA handling by bovine 
chromaffin cells, these cells were maintained in culture for four days and then submitted to 
mono- , trans- and polyunsaturated fatty acids exposure for 24 hours. After these treatments, 
the following parameters were evaluated: CA total and cellular content, basal and KCl-
stimulated release and mRNA levels of TH and PNMT. 
Under control conditions, the average cellular content at the end of the experiments 
was found to be 604  33 and 228  21 nmol/mg protein for AD and NA, respectively. Basal 
release (expressed as % of the total amine content), during 10 minutes of pre-incubation, 
was 15  1 % and 14.5  1 % for AD and NA, respectively. The release of AD and NA was 
increased by excess KCl respectively to about 331  25 % and 295  36 % of control.  MTT 
assays showed that chronic treatment with the several fatty acids at 50 and 100 µM did not 
interfere with cellular viability. 
 
1. Catecholamine total content 
Regarding the CA total content (including cellular content plus release), representing 
the total production of CA, we observed that EA, γ-LIN and LA, at the same concentration 
(100 µM), significantly decreased the content of AD and did not affect NA levels. The AD 
total content achieved after EA, γ-LIN and LA treatments (n=4-8) was respectively 725  84 
nmol/mg protein, 427  57 nmol/mg protein and 127  18 nmol/mg protein.  
Figure 12. Catecholamine total content in bovine chromaffin cells after chronic treatment (24 hours) with eicosapentaenoic acid 
(A) (n=15–16), docosahexaenoic acid (B) (n=13–16), oleic acid (C) (n=7–8) and elaidic acid (D) (n=7–8), at 50 µM and 100 µM. 
After this treatment, cells were pre-incubated for 10 min and incubated during 15 min under different experimental conditions. 
EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid; OA: oleic acid; EA: elaidic acid; AD: adrenaline; NA: noradrenaline; 
CA: catecholamines. Results are presented as arithmetic means ± SEM. * P < 0.05, compared with control.  
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LA was the most potent fatty acid in this effect: 127  18 nmol/mg protein (n=4) vs 
560  132 nmol/mg protein (n=12) in control conditions.  (Figure 12 D and Figure 13 A, B). 
DHA (Figure 12 B) and AA (Figure 13 C), in both concentrations, were able to significantly 
decrease AD and NA total content. On the contrary, Figure 12 (A and C), shows that neither 
EPA nor OA significantly affected total content of CA.  
 
Figure 13. Catecholamine total content in bovine chromaffin cells after chronic treatment (24 hours) with Υ-linolenic acid (A) 
(n=4–8), linoleic acid (B) (n=8–12) and arachidonic acid (C) (n=10–20), at 50 µM and 100 µM. After this treatment, cells were 
pre-incubated for 10 min and incubated during 15 min under different experimental conditions. Υ-LIN: Υ-linolenic acid; LA: 
linoleic acid; AA: arachidonic acid; AD: adrenaline; NA: noradrenaline; CA: catecholamines. Results are presented as arithmetic 
means ± SEM. * P < 0.05, compared with control.  
 
2. Catecholamine cellular content 
 
In good agreement with what was observed for CA total content, EA and LA, at both 
concentrations, diminished the cellular content of AD and did not affect NA. For both fatty 
acids, this reduction was concentration dependent. When the higher concentration of EA and 
LA was used, AD cellular content was greatly reduced respectively to about 51% and 14%, in 
comparison with controls (Figure 14 D and F). γ-LIN was also able to promote a decrease of 
AD cellular content, but only at a concentration of 100 µM (Figure 14 E). AA was the only 
fatty acid that affected the cellular content of both CA, leading to a decrease of their content 
(Figure 14 G). The highest reduction in AD and NA cellular contents, respectively to 28% and 
22% of control, was achieved with the lower concentration (50 µM) of this fatty acid.  On the 
other hand, EPA, DHA and OA, did not significantly modify CA cellular content (Figure 14 A, 
B and C). 
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Figure 14 Catecholamine cellular content in bovine chromaffin cells after chronic treatment (24 hours) with eicosapentaenoic 
acid (A) (n=15–16), docosahexaenoic acid (B) (n=13–16), oleic acid (C) (n=7–8), elaidic acid (D), (n=7–8) Υ-linolenic acid (E) 
(n=4–8), linoleic acid (F) (n=8–12) and arachidonic acid (G) (n=10–20), at 50 µM and 100 µM. After this treatment, cells were 
pre-incubated for 10 min and incubated during 15 min under different experimental conditions. EPA: eicosapentaenoic acid; 
DHA: docosahexaenoic acid; OA: oleic acid; EA: elaidic acid; γ-LIN: γ-linolenic acid; LA: linoleic acid; AA: arachidonic acid; AD: 
adrenaline; NA: noradrenaline; CA: catecholamines. Results are presented as arithmetic means ± SEM. * P < 0.05, compared 
with control.  
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3. Catecholamine basal release 
 
In relation to basal release, AA and EA did not differentiate between AD or NA, but 
had opposite effects over both amines: AA significantly augmented their basal release in the 
same degree (to about 171% and 173%, respectively for AD and NA) (Figure 16 C), whereas 
EA inhibited the release of these amines (by about 28% and 51%, respectively for AD and 
NA) (Figure 15 D).  
The chronic exposure to EPA and DHA lead to a significant reduction of NA basal 
release, respectively to about a maximum of 72% and 62% of control (n=13-15) (Figure 15, 
respectively A and B), but had no effect over AD.  Contrary to the above fatty acids, γ-LIN, at 
the lowest concentration used, was able to selectively decrease the release of AD to about 
71% of control (n=8) (Figure 16 A). On the other hand, as can be seen respectively in 
Figures 16 B and 15 C, LA and OA did not change the basal release of both CA.  
 
 
Figure 15. Catecholamine basal release in bovine chromaffin cells after chronic treatment (24 hours) with eicosapentaenoic 
acid (A) (n=15–16), docosahexaenoic acid (B) (n=13–16), oleic acid (C) (n=7–8) and elaidic acid (D) (n=7–8), at 50 µM and 100 
µM. After this treatment, cells were pre-incubated for 10 min and incubated during 15 min under different experimental 
conditions. EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid; OA: oleic acid; EA: elaidic acid; AD: adrenaline; NA: 
noradrenaline; CA: catecholamines. Results are presented as arithmetic means ± SEM. * P < 0.05, ** P = 0.072, compared with 
control.  
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Figure 16. Catecholamine basal release in bovine chromaffin cells after chronic treatment (24 hours) with Υ-linolenic acid (A) 
(n=4–8), linoleic acid (B) (n=8–12) and arachidonic acid (C) (n=10–20), at 50 µM and 100 µM. After this treatment, cells were 
pre-incubated for 10 min and incubated during 15 min under different experimental conditions. γ-LIN: γ-linolenic acid; LA: 
linoleic acid; AA: arachidonic acid; AD: adrenaline; NA: noradrenaline; CA: catecholamines. Results are presented as arithmetic 
means ± SEM. * P < 0.05, compared with control. 
 
 
4. Catecholamine KCl-stimulated release 
 
As shown respectively in figure 17 A, B and G, EPA, DHA and AA, in a concentration 
independent manner, were able to significantly decrease the release of both CA induced by 
KCl. Among these, the most effective in this inhibitory action upon depolarization by KCl, 
were DHA (100 µM) and EPA (50 µM), respectively for AD and NA. On the other hand, EA 
and γ-LIN (Figure 17 D and E) selectively decreased the release of AD (respectively to about 
79% and 76% in comparison with the release induced by KCl). 
LA was the only fatty acid capable to significantly augment the KCl-stimulated release 
of AD and NA (to about 207% and 187%, respectively), but only at 100 µM (n=4) (Figure 17 
F). Lastly, as shown in Figure 17 C, OA did not significantly affect KCl-stimulated CA release. 
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Figure 17. Catecholamine KCl-stimulated release in bovine chromaffin cells after chronic treatment (24 hours) with 
eicosapentaenoic acid (A) (n=15–16), docosahexaenoic acid (B) (n=13–16), oleic acid (C) (n=7–8), elaidic acid (D) (n=7–8), Υ-
linolenic acid (F) (n=4–8), linoleic acid (G) (n=8–12) and arachidonic acid (H) (n=10–20), at 50 µM and 100 µM. After chronic 
treatment, cells were pre-incubated for 10 min and incubated during 15 min in the absence (control) or presence of KCl (50mM). 
EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid; OA: oleic acid; EA: elaidic acid; γ-LIN: γ-linolenic acid; LA: linoleic 
acid; AA: arachidonic acid; AD: adrenaline; NA: noradrenaline; CA: catecholamines. Results are presented as arithmetic means 
± SEM. * P < 0.05, ** P = 0.06, *** P = 0.075, compared with control.  
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5. TH and PNMT mRNA levels 
 
As mentioned in methods, in order to evaluate the expression of both TH and PNMT 
we performed a relative quantification using qRT - PCR with SYBR Green I detection, using 
GAPDH as the housekeeping gene. As seen in Figure 18 A, only EPA was capable to 
significantly change the expression of TH, decreasing its mRNA levels (P = 0.022).  LA, EA, 
EPA, γ-LIN and DHA significantly decreased the expression of PNMT (Figure 18 B), DHA 
being the most effective in this reduction. However, as shown in the Figures 19 and 20, 
neither AA nor OA significantly changed the expression of these enzymes. 
Figure 18.  Comparison of mRNA levels of tyrosine hydroxilase (A) and phenylethanolamine N-methyltransferase (B) in control 
conditions and after chronic treatment (24 h) with linoleic acid, elaidic acid , eicosapentaenoic acid, Υ-linolenic acid and 
docosahexaenoic acid (at 100 μM), by quantitative real-time PCR, using glyceraldehyde-3-phosphate  dehydrogenase (GAPDH) 
as housekeeping gene (n=4 for each group). LA: Linoleic acid; EA: Elaidic acid; EPA: Eicosapentaenoic acid; γ-LIN: Υ-Linolenic 
acid; DHA: Docosahexaenoic acid; TH: Tyrosine hydroxilase; PNMT: Phenylethanolamine N-methyltransferase.  * P < 0.05, 
compared with control (ethanol). 
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Figure 19. Comparison of mRNA levels of tyrosine hydroxilase  (A) and phenylethanolamine N-methyltransferase (B) in control 
conditions and after chronic treatment (24 h) with oleic acid (at 100 μM), by quantitative real-time PCR, using glyceraldehyde-3-
phosphate  dehydrogenase (GAPDH) as housekeeping gene (n=4). OA: Oleic acid; TH: Tyrosine hydroxilase; PNMT: 
Phenylethanolamine N-methyltransferase.    
 
 
 
Figure 20. Comparison of mRNA levels of tyrosine hydroxilase (A) and phenylethanolamine N-methyltransferase (B) in control 
conditions and after chronic treatment (24 h) with arachidonic acid (at 100 μM), by quantitative real-time RT-PCR (n=4). AA: 
Arachidonic acid; TH: Tyrosine hydroxilase; PNMT: Phenylethanolamine N-methyltransferase.   Shown are arithmetic 
means+SEM corresponding to the expression of each test gene relative to Glyceraldehyde-3-phosphate  dehydrogenase 
(GAPDH). 
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Fatty acids, far from being inert carriers of calories, are powerful modulators of cell 
function, altering membrane fluidity, gene transcription and metabolic and inflammatory 
responses (43). This study was designed in order to provide information about the effect of 
unsaturated fatty acids on CA handling from bovine adrenal chromaffin cells.  
In general, our results show that the several fatty acids affected AD and NA handling 
through distinct ways, regardless both the number of carbons and of double bonds. The fatty 
acids tested altered three different parameters: CA synthesis and accumulation, CA basal 
release and response to depolarization by KCl.  
In relation to the synthesis and accumulation of CA, the fatty acids have shown 
distinct behaviors: 1) EA, LA and γ-LIN decreased both parameters only for AD; 2) DHA and 
EPA decreased the synthesis and maintained the CA accumulation; 3) AA did not change 
the synthesis and decreased the accumulation of both CA and 4) OA did not change either 
the synthesis or the accumulation of both CA.  
In fact, EA, LA and γ-LIN affected the production of AD by decreasing PNMT mRNA 
levels, which was reflected on its total and cellular content. On the other hand, EPA affected 
the synthesis of CA since it was able to decrease the mRNA levels of TH and PNMT, but 
curiously maintained total and cellular content. DHA did not affect CA accumulation since it 
maintained the cellular content of both CA, but decreased the production of AD by interfering 
with PNMT levels. In spite of not changing mRNA levels of TH and PNMT, AA diminished the 
accumulation of both CA since it was able to decrease their total and cellular content. OA did 
not affect either the expression of any of the enzymes or the content of CA. 
Similarly to what happened with the synthesis and accumulation of CA, the tested 
fatty acids were able to differentially affect CA basal release. Among all, only AA was able to 
increase the basal release of both CA, whereas neither LA nor OA affected this release. On 
the other hand, EA was capable to decrease the basal release of both CA. Curiously, both 
EPA and DHA and γ-LIN decreased the basal release respectively of NA and AD. At last, 
EPA, DHA and AA were able to decrease the release of both CA induced by depolarization 
with KCl, whereas EA and γ-LIN only decreased the release of AD. On the other hand, LA 
increased the KCl stimulated-release of both CA and OA had no effect on this parameter.  
Epidemiological studies have shown that Mediterranean diet has protective effects 
against cardiovascular disease, cancer risk, and inflammatory and degenerative diseases 
(65). One of the hallmarks of this diet is the presence of olive oil naturally highly enriched 
with monounsaturated fatty acids, namely OA. The above referred effects have been mostly 
related with the interference with lipid peroxidation, immune response, oxidative stress and 
inflammatory responses. Although previous studies, in other models, have shown that OA 
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has the ability to increase intracellular Ca2+ levels (e.g. in rat thymocytes), mostly by 
mobilization of Ca2+ from intracellular stores (42), in our study, OA did not significantly 
change CA handling by chromaffin cells. On the other hand, trans fatty acids have been 
associated with a higher risk of coronary heart disease, insulin resistance, sudden death and 
the impairment of early development and fetal growth (66-69). Some of the mechanisms 
through which trans fatty acids contribute to this higher risk are already described. In fact, 
several works show that they increase LDL plasmatic levels, decrease HDL plasmatic levels, 
raise apolipoprotein B, and also interfere with the function of fatty acids metabolism related 
enzymes, and enhance triglyceride and C reactive protein (CRP) plasmatic levels (67, 68, 
70). Considering the relation between the intake of trans fatty acids and the high incidence of 
coronary heart disease reported in prospective studies, it was already suggested that they 
may affect several risk factors for coronary heart disease (43). Trans fatty acids are present 
in variables quantities in a broad range of foods, and despite legislative intervention and 
health initiatives, dietary fatty acids remain a concern, owing to the addition of industrially 
produced trans fat to foods and the excessive reheating of frying oils (71). The effect of trans 
fatty acids upon CA handling by chromaffin cells were unknown. In our study, EA, the OA 
trans isomer, and the most representative in foods (80-90% of total trans), selectively 
affected AD handling by these cells, decreasing both production and release. Given that 
other authors have shown that EA does not affect Ca2+-induced CA secretion in these cells 
(72), the decrease in CA release was probably a consequence of a lower cellular content. On 
the other hand, regarding PNMT mRNA levels, the ability of EA to alter enzyme gene 
expression was already described in other cellular models (68), whereas the lack of effect 
over TH is somehow in accordance with its inability to alter TH function (72). As mentioned 
before, AD and NA are differently associated with the metabolic syndrome: NA levels are 
correlated with obesity and cardiovascular risk, while AD shows an inverse association with 
cardiovascular mortality (73, 74). Thus, the finding that EA impaired AD cellular availability 
suggests that this can be another mechanism by which trans fatty acids increase 
cardiovascular risk.  
All together, the results obtained after cell exposure to AA suggest that this fatty acid 
affected VMAT function, since it was able to increase the basal release of CA, decrease their 
release after depolarization with KCl and decrease both cellular and total content. In fact, the 
inhibition of VMAT, a reserpine-like effect, could explain the increase of CA basal release 
associated with a lower accumulation of these amines in granules, suggested by a lower 
response after KCl stimulation. On the contrary, in this same experimental model (75) and in 
other cellular types (76), AA and/or its metabolites were able to affect intracellular Ca2+ levels 
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through either activation of Ca2+ channels or mobilization from intracellular stores. Latham el 
al. (77) have also reported that AA potentiates CA secretion and increase the amount of 
SNARE complex, acting exclusively at protein fusion machinery leading to an increase of 
membrane fusogenicity. Taking into account that in our study AA decreased the CA release 
invoked by KCl (thus exocytosis from granules), and increased basal release, it is unlikely 
that the above pathways were involved. On the other hand, since it was already described 
that chromaffin cells express cyclooxygenase (78-80), we cannot exclude that the observed 
effects were mediated by prostaglandins, originated from AA after cyclooxygenase action. In 
fact, chromaffin cells express prostaglandin receptors (81-83) and, several studies in these 
cells, have shown that PGE2, after binding to prostaglandin EP receptor 3 (EP3R), provokes 
a decrease of intracellular Ca2+ mediated by pertussis toxin sensitive G proteins and/or 
insensitive G proteins. This inhibition was voltage-dependent, being reversed by a strong 
membrane depolarization, and preferably targeted Cav2 calcium channels (N- and P/Q-type I 
Ca2+ channels) (84, 85).The above effects are somehow in accordance with our own results 
since AA, probably through its conversion to PGE2, was able to decrease the CA release 
after depolarization by KCl. On the contrary, some authors reported that PGE2 can stimulate 
both Ca2+ influx (86) and Ca2+ release from ryanodine-sensitive intracellular stores (82) 
through EP1R activation.  
Curiously, another omega-6 fatty acid, LA, in contrast to AA, increased the KCL-
stimulated release of both CA without significantly changing their basal release. The ability of 
LA to increase the CA release after depolarization by KCl might be related with either an 
increase of the expression and/or activity of VMAT or an increase of intracellular Ca2+ levels. 
Several studies, in different cells types, have shown the ability of LA to increase intracellular 
Ca2+ values by causing both IP3-dependent Ca2+ release, from endoplasmatic reticulum (42) 
(87), and extracellular Ca2+ influx (42). Actually, in C57BL/6 mice CD36-positive gustatory 
cells, LA was capable to induce an increase of intracellular Ca2+ levels by IP3-dependent 
mechanisms, whereas in CD36-negative gustatory cells it was unable to affect intracellular 
Ca2+ (88). Interestingly enough, fatty acids are ligands for CD36, as referred before, a cellular 
entity associated with their uptake into cells (47). On the other hand, LA, similarly to γ-LIN 
(and, curiously, also to the omega-9 fatty acid, EA) was able to lower both total and cellular 
content of AD, probably in consequence of its inhibition upon PNMT expression.  
Some studies showed that γ-LIN can be converted into dihomo-gama-linolenic acid 
and AA, respectively the precursors for PGE1 and PGE2 (89). Although not exactly the 
same, the results obtained with γ-LIN and AA, at least for the reduction of KCl-induced 
release, could be explained by the conversion of γ-LIN into AA. If this was the case, the 
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activation of EP3R by PGE, originated from AA, could result in a reduction of intracellular 
Ca2+ levels. This combined with the fact that EP3R expression is more strongly associated 
with adrenergic cells (85), can be a plausible explanation for the preferential modulation of 
AD by γ-LIN, regarding its release induced by potassium. As mentioned before, the role of 
omega-6 fatty acids in cardiovascular diseases prevention remains controversial.  
Results of observational epidemiological and clinical trial studies support the 
recommendations for omega-3 fatty acids consumption, with the view to prevent 
cardiovascular events. In this study, EPA was the only fatty acid that significantly changed 
the expression of both synthesis enzymes (TH and PNMT), leading to their reduction, 
whereas DHA only significantly affected the expression of PNMT. Curiously, the decrease of 
mRNA levels induced by these fatty acids did not change the cellular content of both CA.  
The maintenance of CA cellular content could have been achieved primarily by decreasing 
CA release and/or by maintaining TH and PNMT function (for instance, through the increase 
of their activities). In addition, other mechanisms, such as the reduction of CA metabolization 
(through MAO and/or COMT inhibition) and/or an increase of their cellular reuptake (by 
interference with membrane transporters) may have been involved in those effects.   
Both EPA and DHA decreased the CA release induced by KCl. This effect could be 
associated with an impairment of Ca2+ disposal, since several studies have shown that 
omega-3 fatty acids are able to affect intracellular Ca2+ levels through several mechanisms. 
These include: 1) inhibition of Ca2+ and Na+ channels (39, 90); 2) stabilization of Ca2+ 
channels in the inactivated state (91); 3) inhibition of ryanodine receptors (leading to an 
increase of Ca2+ storage) (39, 90); and 4) direct interaction with calcium regulatory enzymes 
(39). In addition, other cellular entities, including several active phospholipases, receptor-
bound enzymes and protein kinases, involved in the regulation of intracellular Ca2+, are 
modulated by omega-3 fatty acids.  
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The major conclusion of this work is that, with the exception of OA, all the 
unsaturated fatty acids tested were able to significantly modify CA handling by chromaffin 
cells. Moreover, the effects observed over CA production and release were not related 
either with the number of carbons or the location of double bonds.  
The omega-3 fatty acids, EPA and DHA, modulated, almost in the same way, CA 
handling by chromaffin cells: they reduced the expression of their synthesis enzymes (in 
the case of EPA, both TH and PNMT), decreased basal and KCl-stimulation release and 
maintained CA cellular content.  
Within the omega-6 series, the fatty acids under study revealed distinct behaviors. 
Data obtained with AA suggest that this fatty acid was able to inhibit the vesicular 
monoamine transporter, an effect similar to reserpine.  On the other hand, (some of) the 
effects observed after AA exposure could have been mediated by prostaglandins, a 
hypothesis that we cannot exclude at this time. Contrary to AA, γ – LIN and LA affected 
the expression of the enzyme responsible for AD synthesis, impairing its disposal. 
Interestingly enough, LA was also able to increase the depolarization by KCl response of 
both CA, which suggest (albeit not changing basal release), an increase of VMAT function 
and/or a direct effect upon intracellular Ca2+ levels.  
Some of the most interesting findings of this study were related with the omega-9 
fatty acids. As a matter of fact, whereas oleic acid, associated with benefic health effects, 
did not affect CA availability, elaidic acid, its trans isomer, known by its adverse health 
effects, decreased the basal release of NA and all the parameters studied related to AD 
handling.  
In order to clarify the intracellular mechanisms underlying the effects of the above 
fatty acids upon CA handling further studies are needed. Intracellular Ca2+ is a good 
candidate for the action of these molecules, and thus its levels need to be measured.   
Several cellular targets could have been affected by the chronic treatment with the 
unsaturated fatty acids, so is the case of vesicular and membrane transporters and also 
the enzymes responsible for CA metabolism. For instance, taking into account the actions 
of AA, the use of reserpine, under the same experimental conditions, could be useful to 
clarify the involvement of AA in VMAT function. Secondly, COX inhibitors could be used in 
order to verify if AA in our cellular model was converted to PGE. In addition, treatment 
with synthetic PGE could elucidate if these molecules are or not able to mimic AA actions. 
Given that some of the fatty acids might have interfered with CA metabolism, study of the 
function of both COMT and MAO could be elucidative regarding the involvement of these 
enzymes. On the other hand, in relation to TH and PNMT we only studied their mRNA 
levels and it would be also relevant to measure their protein levels and activities.  
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Knowledge from future experiments, together with data obtained from “in vivo” 
studies, might help to sustain future nutritional recommendations in order to improve 
health. 
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